EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection for Stroke Diagnosis Device
核心洞察
EMVision Medical Devices (搜索) is expanding its pivotal FDA De Novo trial to include acute ischaemia detection alongside its original haemorrhage detection endpoint for the emu stroke diagnosis device.
The pivotal trial has recruited over 125 patients with no device-related adverse events reported, targeting sensitivity and specificity of >80% for haemorrhage detection.
The company maintains AUD 18.4 million in cash reserves and expects full enrollment by late 2026/early 2027, with the expansion leveraging existing trial infrastructure.
EMVision Medical Devices (搜索) (ASX: EMV) is expanding its pivotal FDA De Novo trial to include acute ischaemia detection, broadening the potential indications for its emu device beyond the original haemorrhage detection endpoint. The strategic expansion leverages existing trial infrastructure and patient cohorts, with the company expecting trial modifications to be modest and incremental.
The addition is designed to broaden potential indications from the initial FDA De Novo clearance, which primarily targets haemorrhage detection. The primary objective for haemorrhage detection remains a sensitivity and specificity of >80%.
Trial Progress and Safety Profile
Pivotal trial recruitment has surpassed 125 patients with no device-related adverse events reported to date. Full enrolment is anticipated by late 2026/early 2027, with sequential cohort readouts to follow shortly thereafter.
The company maintains a solid financial position with AUD 18.4 million in cash reserves as of March 31, 2026. A further AUD 0.4 million non-dilutive payment was received in May 2026 from CRC-P funding, supporting continued trial execution and commercialisation milestones.
Regional Healthcare Applications
Progress is being made on the Regional Benefit Study, which is funded by CRC-P. Site selection is well advanced, with ethics approval anticipated in H2 2026. This study aims to demonstrate accelerated stroke diagnosis and management, particularly for underserved regional patients via telehealth.
Regulatory and Technical Challenges
Adding the ischaemia endpoint introduces regulatory and execution uncertainty, with performance for acute ischaemia detection considered more complex than haemorrhage detection. No performance results for acute ischaemia detection have been reported yet.
The expansion represents a strategic move to potentially accelerate regulatory approval and expand the market potential of the emu device. While this carries inherent execution and regulatory risks related to the new endpoint, the continued progress in patient recruitment and the company's solid funding position provide a supportive backdrop for this development. Successful validation of this new endpoint is critical for the expanded regulatory claim.